Organization typesPrivate Company

Products 1 to 10 of 141

Biotech components: Bacteria
Business models: B2B
Country of production: USA
Country of distribution: USA + Sweden + Canada
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/08/30 11:49 (2 years ago)
Known funding amount: N/A
Funding types: Venture Capital
Industry: Industrial
Market status: Under Development
Organization type(s): Private Company
Product categories: Chemical
Production process: Closed Production
Source: NASEM Database
Trading symbol: N/A
Value chain stage: Input
Acrylic Acid by GC Innovation America + Myriant
Biotech components: Plant
Business models: B2B
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/10/02 15:42 (2 years ago)
Known funding amount: 110,000,000 USD
Funding types: Government + Venture Capital
Industry: Industrial
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Chemical
Production process: Closed Production
Source: NASEM Database
Trading symbol: N/A
Value chain stage: Input
ActoBiotics: AG013 (Oral Mucositis) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (9 months ago)
Date last modified: 2019/09/12 15:12 (9 months ago)
Known funding amount: N/A
Funding types: Government + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Personal Care (Topical) + Medicine
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG017 (Celiac Disease) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (9 months ago)
Date last modified: 2019/09/16 16:28 (8 months ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Health + Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Personal Care (Ingested)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG018 (Rhinosinusitus) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (9 months ago)
Date last modified: 2019/09/12 15:12 (9 months ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG019 (Type 1 Diabetes) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (9 months ago)
Date last modified: 2019/09/12 15:12 (9 months ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Medical Treatment + Medicine
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (9 months ago)
Date last modified: 2019/09/12 15:12 (9 months ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
Adipic Acid by Verdezyne
Biotech components: Plant
Business models: B2B
Country of production: USA
Country of distribution: USA
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/11/08 14:50 (2 years ago)
Known funding amount: 86,500,000 USD
Funding types: Venture Capital
Industry: Industrial
Market status: No longer on the market
Organization type(s): Private Company
Product categories: Chemical
Production process: Closed Production
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Input
Biotech components: Bacteria
Business models: B2B
Country of production: USA
Country of distribution: N/A
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/10/01 10:00 (2 years ago)
Known funding amount: N/A
Funding types: Private Funding
Industry: Industrial
Market status: On the market
Organization type(s): Private Company
Product categories: Chemical
Production process: Closed Production
Source: SynBio Database
Trading symbol: N/A
Value chain stage: Input
Biotech components: Plant
Business models: B2C
Country of production: USA
Country of distribution: N/A
Intended consumer: Consumer
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/08/30 11:49 (2 years ago)
Known funding amount: 909,000 USD
Funding types: Crowdfunding + Private Funding
Industry: Food & Agriculture
Market status: No longer on the market
Organization type(s): Private Company
Product categories: Plant
Production process: Closed Production
Source: NASEM Database
Trading symbol: N/A
Value chain stage: Finished Product